DexCom Stock Gains from GLP-1 Diabetic Users

Key PointsDexCom is a leading maker of continuous glucose monitoring (CGM) systems initially serving Type 1 diabetics, which are around 5% of the diabetes population, with Type 2 being 95%.Diabetes is a growing epidemic expected to reach 780 million people worldwide by 2045.DexCom is expected to launch Stelo, its CGM system for Type 2 diabetics that doesn't require finger sticks, competing directly with Abbott Lab's Freestyle Libre.5 stocks we like better than DexComDexCom Inc. NASDAQ: DXCM is a leading med ...